Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 14-Day Trial for You or Your Team.

Learn More →

Chemotherapy in Metastatic Urothelial Cancer

Chemotherapy in Metastatic Urothelial Cancer For more than a decade, the cisplatin plus doxorubicin and methotrexate plus vinblastine (MVAC) regimen has been the gold standard chemotherapy in bladder cancer, although the toxicity associated with this therapy has hampered its use in many older patients with metastatic disease. In recent years, new active agents have been identified, combinations of new agents with established drugs followed and results have become available on the combination of gemcitabine and cisplatin vs MVAC that have revealed an efficacy-toxicity profile in favor of the gemcitabine-cisplatin regimen. Other new doublet and triplet combinations, comprising new agents as well as incorporating one or two new agents into established regimens have demonstrated significant activity in phase II studies. However, there are no randomized data to show that any of these regimens improves patient survival as compared with either MVAC or cisplatin-gemcitabine. Advances in the understanding of the molecular biology of urothelial cancer will help to identify new biochemical targets for the development of novel therapeutic approaches to treat this cancer. http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png American Journal of Cancer Springer Journals

Chemotherapy in Metastatic Urothelial Cancer

American Journal of Cancer , Volume 1 (1) – Aug 9, 2012

Loading next page...
 
/lp/springer-journals/chemotherapy-in-metastatic-urothelial-cancer-LCKqtlG2Nk
Publisher
Springer Journals
Copyright
Copyright © 2002 by Adis International Limited
Subject
Pharmacy; Pharmacy
ISSN
1175-6357
DOI
10.2165/00024669-200201010-00004
Publisher site
See Article on Publisher Site

Abstract

For more than a decade, the cisplatin plus doxorubicin and methotrexate plus vinblastine (MVAC) regimen has been the gold standard chemotherapy in bladder cancer, although the toxicity associated with this therapy has hampered its use in many older patients with metastatic disease. In recent years, new active agents have been identified, combinations of new agents with established drugs followed and results have become available on the combination of gemcitabine and cisplatin vs MVAC that have revealed an efficacy-toxicity profile in favor of the gemcitabine-cisplatin regimen. Other new doublet and triplet combinations, comprising new agents as well as incorporating one or two new agents into established regimens have demonstrated significant activity in phase II studies. However, there are no randomized data to show that any of these regimens improves patient survival as compared with either MVAC or cisplatin-gemcitabine. Advances in the understanding of the molecular biology of urothelial cancer will help to identify new biochemical targets for the development of novel therapeutic approaches to treat this cancer.

Journal

American Journal of CancerSpringer Journals

Published: Aug 9, 2012

References